"MannKind (NASDAQ:MNKD) earns a D this week, falling from last week’s grade of C. MannKind is a biopharmaceutical company focused on the development and commercialization of therapeutic products for diseases such as diabetes, cancer, inflammatory and autoimmune diseases. The stock also gets an F in Cash Flow. As of Sept. 26, 2012, 15% of outstanding MannKind shares were held short. For more information, get Portfolio Grader’s complete analysis of MNKD stock."

http://investorplace.com/2012/09/6-biotechnology-stocks-to-sell-now-cphd-arql-mnkd/